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http://dx.doi.org/10.1016/j.ccr.2014.04.025SUMMARYORAI family channels have emerged as important players in malignant transformation, yet the way in which
they reprogram cancer cells remains elusive. Here we show that the relative expression levels of ORAI pro-
teins in prostate cancer are different from that in noncancerous tissue. By mimicking ORAI protein remodel-
ing observed in primary tumors, we demonstrate in in vitro models that enhanced ORAI3 expression favors
heteromerization with ORAI1 to form a novel channel. These channels support store-independent Ca2+ entry,
thereby promoting cell proliferation and a smaller number of functional homomeric ORAI1-based store-oper-
ated channels, which are important in supporting susceptibility to apoptosis. Thus, our findings highlight dis-
rupted dynamic equilibrium of channel-forming proteins as an oncogenic mechanism.INTRODUCTION
Calcium is a universal messenger regulating many physiological
functions including cell proliferation and apoptosis, two key pro-
cesses determining normal tissue homeostasis. We and others
have shown that calcium homeostasis is disrupted during
carcinogenesis, thereby leading to deregulated cell proliferation
and suppression of apoptosis (for reviews see Monteith et al.,
2007; Roderick and Cook, 2008; Prevarskaya et al., 2011).
A number of studies have demonstrated that a large, sustained
elevation of the concentration of cytosolic Ca2+ ([Ca2+]c), which is
required for triggering apoptosis in cancer cells, is mainly pro-
vided by store-operated calcium entry (SOCE), mediated by
store-operated channels (SOCs) (Vanden Abeele et al., 2002;
Flourakis et al., 2010; Orrenius et al., 2003). SOCs are locatedSignificance
Normal cell progression to their malignant derivatives is assoc
cellular functions as apoptosis and proliferation. Here, we show
an oncogenic switch mechanism. In particular, ORAI3 remode
tions that disrupt the equilibrium of ORAI channels and favors
by arachidonic acid. This remodeling of Ca2+ signaling in turn in
phenotype. Our study specifically positions these channels at th
idonic acid metabolism, calcium homeostasis, and oncogenesin the plasmamembrane (PM) and are activated by the depletion
of the endoplasmic reticulum (ER) Ca2+ store, in response to the
stimulation of surface receptor-coupled signaling pathways or
ER stress-inducing insults. Molecular players and events result-
ing in SOCE became increasingly clear when one considers the
involvement of two key proteins, STIM1 and ORAI1 (Berna-Erro
et al., 2012a). The first of these acts in the ER membrane as a
[Ca2+]ER sensor, and the second represents a channel-forming
subunit of PM Ca2+-permeable store-operated channel (SOC),
which can be activated upon interaction with STIM1 (Zhang
et al., 2006; Peinelt et al., 2006; Soboloff et al., 2006; Mercer
et al., 2006). Both proteins are members of homologous pro-
tein families that include two STIM isoforms, STIM1 and STIM2
(corresponding to STIM1 and STIM2 human genes), and three
ORAI isoforms, ORAI1, ORAI2, and ORAI3 (corresponding toiated with remodeling of the proteins controlling such major
that prostate cancer cells use ORAI protein redistribution as
ling results from genomic and microenvironment perturba-
the formation of store-independent Ca2+ channels activated
duces cell progression to amore aggressive pro-proliferative
e center ofmolecularmachinery linking dysregulated arach-
is.
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ORAI Proteins Determine Oncogenic Switch in Cancerthe ORAI1, ORAI2, and ORAI3 human genes) (Williams et al.,
2001; Feske et al., 2006).
Characterization of the molecular nature of SOCE has allowed
its general significance to be assessed, as well as that of each of
its components in those processes determining malignant
growth, such as proliferation, apoptosis, and migration (Faouzi
et al., 2011; Motiani et al., 2010; Feng et al., 2010; Yang et al.,
2009; Chen et al., 2013; Berna-Erro et al., 2012b). It has been
shown that the ‘‘classical’’ interaction of STIM1 and ORAI1 un-
derlies SOCE both in native cancer cells from different types of
tumors and in cancer-derived cell lines. At the same time, a num-
ber of important ‘‘nonclassical’’ events involving other members
of STIM and ORAI families, as well as some nonrelated proteins,
have been reported. For example, ORAI1 in human breast can-
cer (HBC) cells is able to interact with the secretory pathway
Ca2+-ATPase to elicit constitutive store-independent Ca2+ entry,
hence promoting tumorigenesis (Feng et al., 2010). In HBC cells,
the molecular composition of SOCE was shown to depend
on the estrogen receptor status shifting from a canonical
ORAI1 configuration in the estrogen receptor-negative cells to
an ORAI3-based one in the estrogen receptor-positive cells,
thereby conferring apoptosis resistance (Motiani et al., 2010,
2013; Faouzi et al., 2011). These data clearly show that ORAI
proteins are involved in the complex machinery of carcinogen-
esis; however, the role of their remodeling in the alteration of cal-
cium entry pathways promoting the switch to a more aggressive
oncogenic cell phenotype still remains poorly characterized
and poses a number of important questions: (1) What is the crit-
ical factor for the observed oncogenic switch: the change in the
expression level of an individual protein or the change in the ratio
of different channel-forming proteins? (2) Does the pathway of
calcium entry (for instance agonist-operated versus store-oper-
ated) determine a cell’s future phenotype? (3) What is the role
of ORAI proteins in cancer progression? In particular, the role
of ORAI3 needs to be delineated, because this protein is
quite exceptional in that it can form both store-dependent and
store-independent Ca2+ entry channels (Shuttleworth, 2012;
Gonza´lez-Cobos et al., 2013). Here we investigated a role for
ORAI proteins as calcium signaling gatekeepers in the cancer
hallmarks of enhanced growth and resistance to apoptosis.
RESULTS
ORAI3 Is Overexpressed in Human PCa Compared with
Healthy Tissues
Before investigating the role of specific ORAI isoforms and
STIM1 in the cancer-related processes of human prostate,
we first compared their mRNA expression in noncancerous
and cancer prostate tissue specimens obtained from resection
surgeries. As shown in Figure 1A, only the mRNA for ORAI3
was strongly overexpressed.
ORAI1 and STIM1 Are SOCE Constituents in PCa Cells
We next used patch-clamp and Ca2+ imaging techniques com-
bined with small interference (siRNA)-mediated knockdown
in order to determine the preferred molecular organization of
SOCE in PCa cells. Store-operated current (ISOC) in LNCaP cells
was activated in patch-clamp experiments by the intracellular
dialysis of a BAPTA-rich (10 mM) pipette solution (Figures 1B20 Cancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc.and 1C). A 48 hr treatment of the cells with specific siRNAs pro-
duced a strong reduction in both mRNA (Figure S1A) and protein
expression (Figure S1B), although the impact on ISOC density
was variable. Figures 1D and 1E show that only ORAI1 or
STIM1 knockdown was correlated with any substantial suppres-
sion of ISOC density. We confirmed this result using an intracel-
lular Ca2+ imaging technique and the SERCA pump inhibitor
thapsigargin (TG) as a store-depleting agent. As expected,
the addition of 2 mM extracellular calcium to LNCaP cells, prein-
cubated for 10 min with TG (1 mM) in Ca2+-free medium to
achieve complete depletion of their ER Ca2+ stores, resulted
in the marked and sustained elevation of [Ca2+]c caused by the
activation of SOCE (Figure 1F). The peak [Ca2+]c elevation, in
relation to SOCE, decreased by approximately 60% and 80%
in LNCaP cells transfected with siRNA against ORAI1 (siORAI1)
or STIM1, respectively, but not with siRNA against other ORAI
members (Figures 1F and 1G). Moreover, similar calcium imag-
ing experiments conducted on androgen-independent PCa
cells, LNCaP C4-2 (Figure S1C available online), PC-3 (Fig-
ure S1D), and DU-145 (Figure S1E), showed that only specific
siRNA-mediated knockdown of either ORAI1 or STIM1 impairs
their TG-dependent Ca2+ entry.
ORAI, but Not STIM1 Isoforms Influence PCa Cell
Proliferation
We next examined how siRNA-mediated silencing affects the
growth of LNCaP cells. In this series of experiments, cells were
transfected with specific anti-STIM1 or anti-ORAI siRNA, and
growth was quantified 7 days after transfection. The number
of viable proliferating cells was measured by 3-(4,5-dimethylth-
iazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (inner salt) assay andmanual counting of viable prolif-
erating cells (Figures 2A and 2B). siRNA-mediated knockdown of
any of the ORAI or STIM isoforms in LNCaP cells did not affect
mitochondrial deshydrogenase (NADH dehydrogenase) activity
(Figure S2A), indicating the preservation of bioenergetic status
of the cells. At the same time, silencingof anyof theORAI proteins
substantially reduced LNCaP proliferation (Figures 2A and 2B),
whereas silencing of STIM1 was without any effect. Similar re-
sults were obtained with LNCaP C4-2, PC-3, and DU-145 cells
(Figures S2B–S2D). The impairment of cell proliferation by ORAI
protein knockout, togetherwith the independence of proliferation
on the level of STIM1 expression, argues against the involvement
of SOCE in these effects. The growth inhibition induced by siRNA
against ORAI isoforms was not due to apoptosis (Figure 2C).
Silencing of ORAI IsoformsMediate a Downregulation of
the Oncogenic Cell-Cycle Protein Cyclin D1, which Is
Involved in G1 Phase Progression
To elucidate the mechanism by which ORAI proteins influence
PCa cell proliferation, we studied the effects of siRNA-mediated
silencing of ORAI isoforms on cell-cycle progression using flow
cytometry. The results of these experiments have shown that
silencing of ORAI1, ORAI2, or ORAI3 in LNCaP cells induced
cell-cycle arrest with a significant accumulation of cells in the
G0/G1 phase and a decrease in the percentage of the cells in
both the S and G2/M phases (Figure 2D). As expected, silencing
STIM1 was ineffective on cell-cycle progression (Figure 2D).
Similar effects were also observed in PC-3 cells (data not
Figure 1. ORAI3 Is Overexpressed in Human PCa Compared to Healthy Tissues but Is Not Involved in SOCE in PCa Cells
(A) PCR quantitation of various ORAI and STIM1 transcripts in PCa compared to healthy tissues.
(B) Traces of base-line current after the rupture of the membrane (1) and fully developed ISOC (2) in representative LNCaP cells, together with the voltage protocol
used to elicit the current.
(C) I-V relationship of a fully-developed ISOC derived from the traces presented in (B).
(D) Representative time courses of the development of ISOC in response to dialysis with a 10 mM BAPTA-containing pipette solution in LNCaP cells subjected to
48 hr siRNA-mediated silencing of ORAI isoforms or STIM1 compared to control anti-luciferase siRNA (siLUC); ISOC amplitude was measured at 100 mV.
(E) Quantification of ISOC amplitudes of the results presented in (D) (n > 10 for each condition).
(F) Representative measurements of TG-activated SOCE, as indicated by [Ca2+]c elevation in LNCaP cells 48 hr after treatment with control (siLUC), anti-ORAI
isoform-specific, or anti-STIM1 siRNA.
(G) Quantification of SOCE of the results presented in (F) (n > 50 for each condition). Data are representative of three independent experiments.
*p < 0.05. Error bars represent means ± SEM. See also Figure S1.
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mulation of LNCaP, DU-145, and PC-3 cells in the G0/G1 phase
in response to anti-ORAI treatments was accompanied by a
decreased expression of a key controller of G1/S phase transi-
tion, cyclin D1 (Figure 2E; Figures S2E and S2F). This would
suggest that the influence of ORAIs on proliferation involves an
induction of cell-cycle initiator genes.
Downregulation of ORAI Isoforms Alters Both Cytosolic
and Endoplasmic Reticulum Calcium Concentration
Leading to ER Stress Response
Because, on the one hand, our results indicate that ORAI but
not STIM isoforms influence PCa cell proliferation without theinvolvement of SOCE, but, on the other hand, it is known that cal-
cium signaling is critically important for proliferation (Machaca,
2010), we next asked what other features of calcium homeosta-
sis besides SOCE may be affected by downregulated expres-
sion of ORAI proteins. Figure 3A shows original traces obtained
from these Ca2+ imaging experiments. Resting [Ca2+]c levels
were significantly decreased by siORAI1, siORAI2, or siORAI3
treatments (Figures 3A and 3B). Moreover, the application of
the Ca2+ ionophore ionomycin (IM, 5 mM), which is able to
completely deplete ER Ca2+ stores in the Ca2+-free extracellular
medium, induced much smaller transient increases in [Ca2+]c in
siRNA-treated LNCaP cells (Figures 3C and 3D), compared
with the respective nontreated controls, suggesting that theCancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc. 21
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Figure 2. ORAI Isoforms, but Not STIM1, Influence PCa Cell Proliferation and G1 Phase Progression by Downregulating Cyclin D1
(A) The percentage of LNCaP cells proliferating after control, ORAI1-3, or STIM1 knockdown was determined by a colorimetric method (see Experimental
Procedures).
(B) Quantification of LNCaP cell viability, as determined by trypan blue exclusion.
(C) Quantification of apoptotic cells, as determined by Hoechst staining, 48 hr after treatment with control or the indicated siRNA.
(D) The cell-cycle distribution of LNCaP cells treated, as above, with the indicated siRNAs for 96 hr, as determined by flow cytometry.
(E) A representative western blot for cyclin D1 (left) and quantification of cyclin D1 protein levels (right) in siORAI knockdown LNCaP cells. The values represent the
relative density of bands compared to the control condition (CTL), which will obviously have a relative density of 1 (n = 3).
*p < 0.05. Error bars represent means ± SEM. See also Figure S2.
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also reduced by ORAI depletion. Similar results were obtained
with PC-3 cells (Figures S3A–S3D).
It is well known that decreased [Ca2+]ER triggers ER stress
and sets off an unfolded protein response (UPR) associated
with the activation of specific ER-resident proteins, such as
PERK, ATF-6, and IRE1a (Hetz, 2012). It has been demonstrated
that activation of the PERK signaling pathway leads to the inhibi-
tion of cyclin D1 expression (Brewer and Diehl, 2000). Western
blot analysis has shown that downregulation of ORAI isoforms
in LNCaP, DU-145, and PC-3 cells leads to the activation of
PERK via phosphorylation in all cell types (Figure 3E; Figure S3E).
We can notice that in LNCaP cells there is some variability with
the weakest response for siORAI1 (Figure 3E). However, these
data are consistent with the notion that ORAI protein deficiency
and the associated decrease in [Ca2+]ER induce UPR.
Endogenous Association of ORAI1 and ORAI3 Channels
to Form Store-Independent Channels Specifically Gated
by Arachidonic Acid in PCa Cells
Because ORAI1, ORAI2, and ORAI3 have been also implicated
in the formation of other SOC Ca2+ entry channel phenotypes
(Smyth and Putney, 2012; Va´rnai et al., 2009; Hogan et al.,
2010; Cahalan, 2009), we next asked what kind of molecular in-22 Cancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc.teractions among ORAI proteins may underlie the observed
changed in Ca2+ homeostasis and proliferation of PCa cells.
Whether ORAI2 alone, in combination with ORAI1 or with yet
unidentified protein(s), forms a distinct store-operated channel
in certain cell types is still a matter of debate. In our hands,
ORAI2 appeared not to be involved in the endogenous SOCE
in PCa cells. However, our data clearly showed that ORAI2
knockdown reduces resting levels of [Ca2+]c (Figure 3A; Fig-
ure S3A), as is consistent with its function in supporting
some sort of background steady-state Ca2+ influx into PCa
cells. As far as ORAI1 and ORAI3 are concerned then, they
can also assemble into a 33ORAI1 plus 23ORAI3 heteropen-
tamer that underlies the unique type of calcium channel,
namely the arachidonic acid-activated channel (ARC) (Mignen
et al., 2009).
Figure 4A shows that the application of exogenous arachi-
donic acid (AA) (8 mM) to LNCaP cells with an approximately
60 s delay activated an inward current that reached a maximal
amplitude of 0.93 ± 0.07 pA/pF (n = 7, at membrane potential
Vm = 100 mV, Figure 4B) within approximately another 60 s.
This current demonstrated the current-voltage (I-V) relationship
with marked inward rectification and a very positive reversal po-
tential (Figures 4C and 4D). siRNA-mediated silencing of either
ORAI1 or ORAI3 significantly suppressed IAA in LNCaP cells
A B C
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Figure 3. ORAI Isoform Knockdown Induces a Decrease in Both Cytosolic and Reticular Calcium Concentration Combined with ER Stress
(A) Resting [Ca2+]c signals in LNCaP cells subjected to siRNA-mediated silencing (48 hr) of the indicated ORAI isoforms compared to control (siLUC).
(B) Quantification of resting [Ca2+]c (n > 150 for each condition).
(C) Representative recordings of IM-induced [Ca2+]c elevation in LNCaP cells.
(D) Quantification of ER Ca2+ content (n > 100 for each condition) from the experiments presented in (C).
(E) Representative western blot of phospho-PERK (P-PERK) in LNCaP cells transfected with control (siLUC) siRNA or siRNA against ORAI isoforms (48 hr; n = 3).
*,p < 0.05. Error bars represent means ± SEM. See also Figure S3.
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forms to support this current.
Activation of Ca2+ entry by AA in LNCaP cells was further
confirmed in calcium imaging experiments in LNCaP cells. As
shown in Figure 4E, exposure of LNCaPcells to AA (8mM) induced
a slow rise in [Ca2+]c up to more than 300 nM. The addition of AA
togetherwithLa3+ (100mM),which is apotent inhibitor of a number
of Ca2+-selective PM channels (Shuttleworth and Thompson,
1998; Mignen and Shuttleworth, 2000), largely prevented AA-
induced [Ca2+]c rise (Figure S4A). Moreover, siRNA-mediated
silencing of either ORAI1 or ORAI3, but not ORAI2 in PC-3 cells,
significantly reduced the calcium influx elicited by AA (Figure 4F).
AA can be generated endogenously in response to a stimula-
tion of M3 muscarinic receptors (M3-AChR) (Shuttleworth and
Thompson, 1998). Application of the nonselective muscarinic
agonist, oxotremorine (Oxo, 10 mM), largely mimicked the
[Ca2+]c rise in PC-3 cells induced by exogenous AA (Figure S4B).
Moreover, Oxo-induced Ca2+ influx in PC-3 cells could be elim-
inated by siORAI1 or siORAI3 treatment (Figure S4B). Previous
studies on ARC channels have shown that they are dependent
on STIM1 levels (Mignen et al., 2008), but our results show that
siRNA knockdown of STIM1 did not alter AA-activated Ca2+ en-
try (Figure S4C). Therefore we performed biotinylation assays
against STIM1 under basal conditions and following TG or AA
treatment in PC-3 and HEK-293 cells (Figure S4D). There was
no expression of STIM1 at the plasma membrane as was sug-
gested for the activation of classical ARC channels. Finally, we
performed additional coimmunoprecipitation assays showing
that in contrast to ORAI1, ORAI3 does not coimmunoprecipitate
with STIM1 under TG exposure in PC-3 cells (Figure S4E).
Collectively, these data confirmed that in prostate models, the
mechanism of AA-controlled calcium entry is different from theclassical ARC channel described by Mignen et al. (2008, 2009).
For these reasons, in the present study, we maintained the
term ‘‘heteromeric association of ORAI1/ORAI3’’ instead of ARC.
We next examined whether AA per se can stimulate PCa cell
growth. As shown in Figure 4G and in Figure S4F, AA or Oxo
were indeed able to stimulate growth of control PC-3 cells
(i.e., transfected with anti-luciferase siRNA [siLUC]), whereas
the proliferation of PC-3 cells transfected with either siORAI1,
siORAI3-1, or siORAI3-2, despite the presence of AA or Oxo,
was greatly reduced.
ORAI3 Controls PCa Cell Proliferation via
Ca2+/NFAT-Dependent Pathways
Wehave previously shown that promotion of human primary PCa
epithelial cell proliferation via TRPC6 or TRPV6 channel-medi-
ated Ca2+ entry, involves the activation of a Ca2+-dependent
transcription factor, which is the nuclear factor of activated
T-cells (NFAT) (The´bault et al., 2006; Lehen’kyi et al., 2007). In
our case, incubation of PC-3 cells with the cell-permeable
NFAT inhibitor peptide (VIVIT; 50 mM for 3 hr) was able to abolish
AA-stimulated proliferation (Figure 4G). Next, we proceeded to
measuring NFAT transcriptional activity in response to the alter-
ations in AA-induced Ca2+ entry caused by impairment of ORAI3
expression. In these experiments, LNCaP or PC-3 cells were
cotransfected with siORAI3 and pCIS-CK plasmid containing
an insert of a luciferase reporter gene driven by a synthetic
NFAT-dependent promoter (pNFAT-Luc plasmid). Figure 4H,
S4G, and S4H show that incubation of pNFAT-Luc-transfected
LNCaP or PC-3 cells in media containing AA (3 mM) or Oxo
(10 mM) results in greater luciferase light emission than in cells
not exposed to AA or Oxo. AA- or Oxo-stimulated luciferase
activity could be greatly reduced by siRNA-mediated ORAI3Cancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc. 23
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Figure 4. Endogenous Association of ORAI1 and ORAI3 Leads to the Formation of Store-Independent, AA-Regulated Channels Involved in
Stimulation of Proliferation via NFAT Signaling.
(A) Representative time courses of the development of inward current in response to AA application in LNCaP cells subjected to the indicated siRNA-mediated
silencing (48 hr). Current amplitude was measured at 100 mV at the onset of hyperpolarization (see C).
(B) Quantification of current amplitudes shown in (A; n > 6 for each condition).
(C) Representative original traces of base-line current (1) and fully developed current in LNCaP cells in response to AA (8 mM) application (2) in LNCaP cell together
with the voltage protocol used to elicit the currents.
(D) I-V relationship of a fully-developed current derived from the traces presented in (C).
(E) [Ca2+]c rise in LNCaP cells in response to AA (horizontal bar). CTL, control.
(F) [Ca2+]c responses of control PC-3 cells (siLUC) and PC-3 cells subjected to anti-ORAI isoform-specific siRNAs treatment (48 hr) to AA.
(G) Quantification of the percentage of baseline and AA-stimulated proliferation of control PC-3 cells. Pretreatment with the cell-permeable NFAT inhibitor peptide
(VIVIT; 50 mM; 3 hr) abolished AA-mediated proliferation.
(H) Quantification of luciferase-reported baseline and AA-stimulated NFAT activity in PC-3 cells.
(I) Confocal images of NFAT-GFP fluorescence in live PC-3 cells transiently transfected with NFAT-GFP during vehicle control (CTL, upper panel) or AA (lower
panel) application showing AA-induced NFAT translocation to the nucleus.
*p < 0.05. Error bars represent means ± SEM. See also Figure S4.
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nucleus, as was assayed on PC-3 cells transiently transfected
with NFAT-GFP construct (Figure 4I). Overall, the results of these
experiments strongly suggested that endogenous AA-activated
channels in PCa cells formed by ORAI1 and ORAI3 proteins
are highly likely to be involved in cell proliferation, by providing
the Ca2+ entry required for the induction of transcriptional activity
of the Ca2+-dependent transcription factor, NFAT.
ORAI1/ORAI3 Ratio Modulates Basal [Ca2+]c and Size
of SOCE
To further characterize the significance of ORAI3 in the mainte-
nance of Ca2+ homeostasis, we took advantage of the fact that24 Cancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc.PC-3 cells express lower levels of endogenous ORAI3 mRNA
(Figure S5A) than LNCaP cells do (see Figure S1D). As shown
in Figure 5A, transient overexpression of ORAI3 in PC-3 cells re-
sulted in the notably higher resting [Ca2+]c levels than in the con-
trol PC-3 cells at regular 2 mM external Ca2+ concentrations
([Ca2+]o; see also Figure S5B). Moreover, increasing [Ca
2+]o in
the bathing solution from 0 to 10 mM produced more significant
elevations of the basal [Ca2+]c in ORAI3-overexpressing PC-3
cells than in the control ones (Figure 5A; Figure S5C). This would
suggest that ORAI3 specifically promotes enhanced basal Ca2+
influx and not Ca2+ liberation from intracellular sources. Intrigu-
ingly, the use of TG (1 mM) for the selective activation of SOCE
showed that ORAI3 overexpression resulted not in the increase
A B C
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Figure 5. Both the ORAI1/ORAI3 Ratio and AA-Regulated Ca2+ Entry Promote Apoptosis Resistance and Cell Proliferation by Controlling
basal [Ca2+]c and Amplitude of SOCE
(A) [Ca2+]c in the presence of 0, 2, or 10 mM extracellular Ca
2+ and after TG treatment in PC-3 cells transiently overexpressing ORAI3 (green line) compared to
control cells (black line).
(B) Quantification of ORAI3 mRNA in two PC-3 clones stably overexpressing ORAI3 relative to a control clone (PC-3-siLUC clone 1). Both clones showed higher
AA-stimulated calcium entry (right panel).
(C and D) [Ca2+]c responses of PC-3-CTL clone 1 and PC-3-ORAI3 clone 1 and clone 2 cells to TG (1 mM) alone (C) or after pretreatment with AA (D, 25 min of
treatment with 10 mM AA).
(E) Quantification of [Ca2+]c responses from experiments presented in (C and D) (n > 100 for each condition).
(F) Quantification of the effects of ORAI3 overexpression in PC-3 cells on luciferase-reported baseline NFAT activation.
(G) Quantification of the percentage of baseline proliferation of control and ORAI3-overexpressing PC-3 clones (n = 3) for each clone.
(H and I) Quantification of TG-induced apoptosis [0.5 mM/48 hr (H); 2 mM/48 hr (I)] of control and ORAI3-overexpressing clones and with AA treatment (3 mM; n = 3)
for each clone.
*p < 0.05. Error bars represent means ± SEM. See also Figure S5.
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SOCE in PC-3 cells (Figure 5A; Figure S5D). Because both
ORAI1 and ORAI3 can potentially be involved in SOCE, these
results indicate that ORAI3 overexpression, on the one hand,
leads to the enhancement of the basal store-independent
Ca2+ entry and, on the other hand, suppresses the store-depen-
dent one. Such a situation can only be explained if we conclude
that higher ORAI3 levels, in the presence of a limited ORAI1
supply, favor the formation of heteromeric ORAI1-ORAI3-based
channels, thence contributing to the basal, nonstimulated influxof Ca2+ at the expense of homomeric ORAI1- or ORAI3-based
SOCs.
In LNCaP cells, neither overexpression of ORAI3 nor its siRNA-
mediated knockdown had any significant impact on the size
of TG-activated SOCE (Figure S5E). The lack of the influence
of ORAI3 overexpression on SOCE amplitude in LNCaP cells
was most probably explained by the higher basal expression
of ORAI3 than in PC-3 cells. When control LNCaP cells were
exposed to AA (10 mM), the cytosolic calcium concentration
slowly increased (Figure S5F). The subsequent addition of TGCancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc. 25
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lated with AA (Figure S5E). We also confirmed these data on
primary human prostate cancer cells (Figure S5G–S5I). Finally,
we performed coimmunoprecipitation assays showing that
ORAI3 overexpression (PC-3-ORAI3 clone 1) virtually abolished
ORAI1 coimmunoprecipitation with STIM1 under TG exposure
compared with PC-3-CTL clone 1 (Figure S5J). Collectively,
these data strongly suggest that the activation of endogenous
store-independent channels by AA recruits ORAI1 isoforms to
oligomerize with ORAI3, thereby inhibiting SOCE.
ORAI3 Overexpression Stimulates Cell Proliferation and
Promotes Apoptosis Resistance
To further investigate the significance of ORAI3 in Ca2+ signaling
and cancer cell growth, we produced PC-3 cells with stable
ORAI3 overexpression. To avoid clonal variations in the proper-
ties, two clones of PC-3 cells that overexpress ORAI3, PC-3-
ORAI3 clone 1 and PC-3-ORAI3 clone 2, and two clones,
PC-3-CTL clone 1 and PC-3-CTL clone 2, which served as
respective controls, were created and analyzed. Overexpression
of ORAI3 mRNA in PC-3-ORAI3 clone 1 and clone 2 cells was
confirmed by real-time PCR (Figure 5B, left panel). As with tran-
sient ORAI3 overexpression in PC-3 cells, both clones showed
higher AA-stimulated calcium entry (Figure 5B, right panel) and
lower TG-stimulated SOCE (Figure 5C) than in the respective
controls. This was most likely due to the preferred formation of
endogenous store-independent Ca2+ channel specifically gated
by AA at the expense of homomeric ORAI1- or ORAI3-based
SOCs. Moreover, a greater reduction of TG-activated SOCE in
either control or ORAI3-overexpressing clones of PC-3 cells
could be achieved by cell pretreatment with AA (25 min with
10 mM AA) (Figures 5D and 5E). This is consistent with the notion
that AA per se serves as a promoting factor for ORAI1 andORAI3
heteromerization. In addition to this, luciferase assay revealed
much higher basal NFAT activity in PC-3-ORAI3 clone 1 and
clone 2 cells (Figure 5F), as well as their significantly enhanced
AA-stimulated proliferation when compared to the respective
controls (Figure 5G).
Our previous studies have shown that enhanced apoptosis
resistance of androgen-independent PCa cells is largely
conferred by their reduced SOCE (Vanden Abeele et al., 2002;
Prevarskaya et al., 2004; Flourakis et al., 2010). In full agreement
with this fundamental finding, both PC-3-ORAI3 clone 1 and PC-
3-ORAI3 clone 2, which had their SOCE reduced, demonstrated
lower sensitivity to the TG-induced apoptosis (Figure 5H).
Increasing concentrations of TG to 2 mM significantly enhanced
apoptosis of PC-3-ORAI3 clone 1 and clone 2 cells (Figure 5I).
However, cotreatment with AA exerted a greater protective
effect (Figure 5I), most likely because of promotion by AA of
ORAI1 isoforms to oligomerize with ORAI3, thereby resulting in
a greater reduction in SOCE (Figures 5D and 5E).
The Dynamics of ORAI1 and ORAI3 Subcellular
Distribution in PCa Cells
To locate ORAI1 andORAI3 proteins, we performed confocal im-
aging of PC-3 cells immunostained with anti-ORAI1 (green) and
anti-ORAI3 (red) antibodies. After treatment with TG (1 mM, 5min)
ORAI1 staining became notably denser at the cell’s periphery
(Figure 6A). The addition of AA (10 mM) to the incubation medium26 Cancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc.had no visible effect on the pattern of ORAI1 and ORAI3 staining.
The addition of AA (10 mM) together with TG (1 mM) to the incuba-
tion medium partially reversed the peripheral ORAI1 staining
induced by TG with little effect on the pattern of ORAI3 staining.
In ORAI3-overexpressing PC-3 cells (Figure 6B), transition to
heavy peripheral ORAI1 staining in response to TG (1 mM) was
prevented. AA, when applied alone, induced a formation of hemi-
sphere-shaped areas of ORAI1 and ORAI3 staining. Finally, in
ORAI3-overexpressing PC-3 cells, AA (10 mM) was also able to
completely prevent any heavy peripheral ORAI1 staining induced
by TG (1 mM). Original traces (Figure S6A) and histograms (Fig-
ures S6B–S6D) show quantification of the peripheral peak of
ORAI1 and ORAI3 fluorescence. These data suggest an impair-
ment of the SOCE mechanism induced by AA.
Treatment of PCa Cells with Arachidonic Acid Enhanced
the Association between ORAI1 and ORAI3.
We also investigated membrane targeting and association of
ORAI1 and ORAI3 in PC3 cells. Cell-surface biotinylation of
PC3 cells treated with AA or Oxo showed no significant variation
in plasma membrane ORAI3 expression, ruling out its possible
rapid translocation to plasma membrane (Figure 6C). AA
or Oxo treatments of PC-3 cells also did not change ORAI3 pro-
tein expression (Figure 6D). In addition, coimmunoprecipitation
from lysates of PC3 cells with either anti-ORAI1 (Figure 6E, left
panel) or anti-ORAI3 (Figure 6E, right panel) antibodies showed
formation of endogenous heteromeric complexes by ORAI1
and ORAI3 proteins. Moreover, Ca2+ store depletion by TG
decreased the association of ORAI1 with ORAI3 (Figure 6F, mid-
dle panel), whereas a consecutive treatment with AA (10 mM,
30 min) and TG (1 mM, 10 min) promoted such association (Fig-
ure 6F, right panel). In a complementary series of experiments,
we sought to strengthen our hypothesis that ORAI3 overexpres-
sion alone without any AA treatment is sufficient to promote
basal ORAI1 oligomerization with ORAI3, resulting in an inhibi-
tion of SOCE. In this series, we transiently overexpressed
different ratios of ORAI1, STIM1, and ORAI3 in prostate cancer
cells to mimic what happens during prostate cancerogenesis
and examined how it affects ORAI1 and STIM1 coimmunopreci-
pitation, as well as SOCE under TG exposure (Figures S6E and
S6F). They show that at a ratio of 1:1:1 (1 mg of each plasmid
per 2ml petri dish), SOCE becomes decreased by approximately
38% compared to a ratio 1:1:0, indicating that just the presence
of ORAI3 is sufficient to inhibit SOC-mediated calcium entry.
Increasing the proportion of ORAI3 by a factor of 3 (i.e., to a ratio
1:1:3), typical of prostate carcinogenesis, produced even stron-
ger inhibition of SOCE amplitude by approximately 62%.
We next usedORAI1-YFP construct to enable ORAI1 tracing in
PC-3 cells in confocal imaging experiments during overexpres-
sion of different ratios of ORAI1, ORAI3, and STIM1 (see Figures
S6G and S6H). At a 1:1:0 ratio, ORAI1 staining showed quite
diffused distribution under control condition, but after treatment
with TG (1 mM, 5 min), the staining became notably denser at
the cell’s periphery. At a ratio of 1:1:1, peripheral ORAI1 staining
induced by TGwas partially reversed, whereas at a ratio of 1:1:3,
TG virtually failed to induce peripheral ORAI1 staining.
Finally, we performed coimmunoprecipitation assays showing
that at a ratio 1:1:3ORAI3overexpressiondecreasesORAI1coim-
munoprecipitation with STIM1 under TG exposure compared
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Figure 6. ORAI1/ORAI3 Ratio and AA-Regulated Ca2+ Entry Control the Dynamics of ORAI1 and ORAI3 Subcellular Distribution
(A) Confocal images of immunocytochemical detection of ORAI1 (green), ORAI3 (red), and merged images (yellow) in resting state wild-type PC3 cells and at the
indicated time after treatment with 1 mM TG, with 10 mM AA, or with consecutive AA (10 mM) and TG (1 mM) treatment.
(B) Images as in (A), but for PC-3 cells with transient ORAI3 overexpression. The yellow arrow indicates untransfected cells, and white rectangles present the
fluorescence intensity of ORAI1 or ORAI3 from the shown selected and magnified areas.
(C) Western blots of ORAI3 in total (full lysate) and biotinylated (PM) protein fractions of control (CTL) treated PC3 cells and following treatment with AA (8 mM) or
Oxo (10 mM) for 30 min (n = 3).
(D) Western blots of ORAI3 protein levels in CTL treated PC-3 cells and cells pretreated with AA or Oxo (n = 3).
(E) Immunoblots (IB) for ORAI3 (left) or ORAI1 from total PC3 cell lysates (input) or lysates immunoprecipitated (IP) with either ORAI1 or ORAI3 antibodies (n = 3).
(F) IB for ORAI3 from lysates immunoprecipitated with ORAI1 and following indicated treatments. The values represent the relative density of bands compared to
the ORAI1 IP fraction in control condition, which will obviously have a relative density of 1 (n = 3).
*p < 0.05. Error bars represent means ± SEM. See also Figure S6.
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support our hypothesis that either ORAI3 overexpression or AA
per seserve topromoteORAI1oligomerizationwithORAI3, result-
ing in the formation of endogenous store-independent Ca2+ chan-
nel specifically gated by AA with a simultaneous inhibition of
SOCE.
Oncogenic Role of ORAI3 in Xenograft Tumor Assays
Our results suggest that ORAI3 protein can be regarded as an
oncogenic one, because its overexpression, on the one hand, fa-
vors the formation of a PM Ca2+-permeable channel that stimu-lates PCa cell proliferation and, on the other hand, disfavors the
expression of the channel that is important in supporting suscep-
tibility to apoptosis. We conducted experiments on mouse pros-
tate tumor xenografts using the strategy of siRNA-mediated
ORAI3 knockdown. In our experiments, to achieveORAI3 knock-
down, mice with PC-3 cell-induced xenograft tumors were in-
jected intraperitoneally (i.p.) on a daily basis with two different
anti-ORAI3 siRNAs: siORAI3-1 and siORAI3-2 (to exclude
nonspecific effects of siRNAs). Results of these experiments
have shown that siRNA-treated animals displayed significantly
reduced tumor growth compared with the animals treated withCancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc. 27
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Figure 7. The Effects of ORAI3 on In Vivo Xenograft Tumors
(A) The relative volume of PC-3 cell xenograft tumors over time in nude mice treated for 2 weeks with control siLUC (n = 7) or with two siRNAs against ORAI3
(siORAI3-1, n = 6; and siORAI3-2, n = 6).
(B) Representative photographs of the indicated siRNA-treated and untreated animals.
(C) Xenograft tumor weights after 2 weeks of siRNA treatment.
(D and E) Western blots showing ORAI3 (D, left panel) and cyclin D1 (E) protein levels in siLUC and siORAI3-2 PC3 tumors. ORAI3 relative expression normalized
to levels of b-actin is shown (D, right panel).
(F andG) Tumor volume over time (F) and tumorweight (G) from two control (PC-3-CTL clone 1 and 2) and twoORAI3-overexpressing clones (PC-3-ORAI3 clone 1
and PC-3-ORAI3 clone 2) 3 weeks after xenograft induction in nude mice (n = 6 for each tumor type).
(H) ORAI3 protein expression in PC-3-CTL clone 1 and PC-3-ORAI3 clone 1 tumors as determined by western blot.
*p < 0.05. Error bars represent means ± SEM. See also Figure S7.
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treated with anti-ORAI3 siRNAs correlated with a downregula-
tion of ORAI3 protein (Figure 7D) and cyclin D1 expression (Fig-
ure 7E), which would suggest that specific therapeutic targeting
of ORAI3 affects cancer cell proliferation. In contrast, mouse
xenografts from either PC-3-ORAI3 clone 1 or clone 2 cells
were characterized by accelerated tumor growth (Figure 7F),
higher tumor weight (Figure 7G), and overexpression of ORAI3
(Figure 7H). We also conducted additional series of in vivo exper-
iments, in which the effects of ORAI1 silencing in PC-3-ORAI3
clone 1 cells was examined. These experiments have demon-
strated an inhibition of tumor growth inmice treatedwith siORAI1
(Figure S7A), which correlated with a downregulation of cyclin D1
(Figures S7B and S7C) and ORAI1 expression (Figures S7B and
S7D). Thus, the enhanced tumor growth observed with ORAI3
overexpression (Figure 7F) appears to be not only ORAI3-depen-
dent, but also dependent on the pool of ORAI1 protein, which, at28 Cancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc.least in part, can be explained by the requirement of heteromeric
ORAI1/3 channel formation for sustaining such growth.
DISCUSSION
In this study, we report four findings for the understanding of the
Ca2+ dependence of prostate carcinogenesis (Figure 8). ORAI1
is the key subunit involved in the formation of homomultimeric
plasma membrane SOC in PCa epithelial cells. PCa progres-
sion is associated with enhanced ORAI3 protein expression.
An increased level of endogenous ORAI3 protein in PCa cells
favors the preferred association of ORAI3 with ORAI1 to form
heteromultimeric store-independent AA-regulated channels at
the expense of homomultimeric ORAI1-based SOCs. Also,
derivation of AA-regulated channels at the expense of SOCs
caused by altered ORAI1/ORAI3 ratio represents an oncogenic
switch in preferred Ca2+ entry pathway that promotes PCa cell
Figure 8. Disrupted Dynamic Equilibrium of ORAI Channels Simultaneously Contributes to Two Cancer Hallmarks: Enhanced Growth and
Resistance to Apoptosis
Cancer Cell
ORAI Proteins Determine Oncogenic Switch in Cancerproliferation and confers apoptosis resistance. These findings
demonstrate the functional significance of store-independent
AA-regulated channels in cancer cells in providing the Ca2+ influx
required for cells proliferation and the switch to an oncogenic
phenotype.
Arachidonic Acid-Regulated Channels in Prostate
Cancer Cells
The concept of ARC emerged in 2000 (Mignen and Shuttleworth,
2000), based on the previous series of studies of agonist-evoked
Ca2+ entry in response to the low agonist concentrations, insuf-
ficient to produce substantial emptying of the ER Ca2+ stores. It
was established that the messenger responsible for the activa-
tion of Ca2+ entry under these circumstances is a receptor-stim-
ulated derivation of AA. With the discovery of STIM and ORAI
proteins as critical determinants of Ca2+ entry mechanisms in
nonexcitable cells, it was also determined that the ‘‘classical’’
functional ARC channel is formed by a heteropentameric assem-
bly of three ORAI1 and two ORAI3 subunits, whose activation
also requires the constitutive presence of a discrete pool of
PM-resident STIM1 (Mignen et al., 2009). Our data suggest
that overexpression of ORAI3 in PCa cells leads to the derivation
of Ca2+-permeable channels with similar subunit compositionand functional features to classical ARC channels, yet we may
already say that such overexpression shifts the balance in
preferred Ca2+ entry pathways from store-dependent ones to
those whose activation is dependent on AA. Indeed, the bio-
physical properties of the corresponding membrane current in
PCa cells, such as strong inward rectification and lack of distinct
reversal potential, are similar to those described previously for
ARC (Mignen and Shuttleworth, 2000; Mignen et al., 2009). How-
ever, our results show that siRNA knockdown of STIM1 does not
alter AA Ca2+ signaling. Moreover, neither coimmunoprecipita-
tion nor biotinylation assays were able to confirm the implication
of STIM1 in themechanism of AA-mediated calcium entry in PCa
cells. These results suggest that in prostate models, the mecha-
nism of AA-mediated calcium entry differs from the classical
ARC channel described by Mignen et al. (2009). For these rea-
sons, in the present study, we maintained the term ‘‘heteromeric
association of ORAI1/ORAI3’’ instead of ARC.
Functional Significance of AA-Activated Ca2+ Influx in
Prostate Cancer Cells
We also demonstrated that the signaling pathway via which AA-
activated Ca2+ influx promotes proliferation of PCa cells involves
the activation of a Ca2+/calcineurin-dependent transcriptionCancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc. 29
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key rate-limiting controller of G1/S phase transition, cyclin D1.
Thus, in terms of a preferential effect on proliferation, ORAI1/
ORAI3-based channels in PCa cells are quite similar to TRPC6
channels, which have also been shown to support the Ca2+ entry
that is specifically linked to NFAT-mediated transcriptional activ-
ity promoting the expression of cell cycle regulators (The´bault
et al., 2006). However, the activation of TRPC6 is coupled to
a1-adrenoreceptor (a1-AR) signaling (The´bault et al., 2006),
whereas here we show that endogenous store-independent
ARC activation is associatedwithmuscarinicmAChR-stimulated
derivation of AA. This suggests that stimulation of both types of
receptors, a1-AR and mAChR, confer greater proliferation on
PCa cells, and consequently the suppression of a1-AR- and/or
mAChR-mediated signaling may be considered as adjuvant
therapy in PCa treatment.
Moreover, the AA signaling pathway that incorporates phos-
pholipase, cyclooxygenase, lipoxygenase, and epoxygenase
enzymes has been shown to play amajor role in the development
and progression of a number of cancers (Nakanishi and Rosen-
berg, 2006), including PCa. The inhibition of AA production has
been shown to decrease prostate-specific antigen expression
and PCa growth in preclinical studies (Patel et al., 2008). There
is also a positive correlation between carcinogenesis and dietary
intake of both the omega-6 fatty acid precursor linoleic acid and
its product AA (Phinney, 1996). Our work provides a solution to
resolve some roles of tumor microenvironment perturbations
and the role of nerves in tumor growth and progression in PCa.
Indeed, a recent study by Magnon et al. (2013) demonstrated
in in vivomouse models of the nerve fibers from the parasympa-
thetic nervous system, which deliver acetylcholine, the role of
nerves in tumor growth and progression in PCa. These findings
bring evidence suggesting that ORAI3 may represent a thera-
peutic target in PCa. Considering that we demonstrate that the
ORAI1/3 heteromer promotes proliferation following stimulation
of M3 muscarinic receptors (M3-AChR), these results fit with
the notion that PCa progression mediated by parasympathetic
cholinergic fibers is at least partly due to ORAI1/3 heteromers.
Thus, our study provides insight into the role of AA in oncogen-
esis by establishing a direct link between AA metabolism and
PCa cells proliferation via the involvement of AA-regulated
Ca2+ entry.
Role of ORAI Proteins in Prostate Cancer Hallmarks
Our findings reveal a mechanism via which PCa cells, by chang-
ing the expression of a single protein (i.e., ORAI3), can simulta-
neously promote two key oncogenic hallmarks: enhanced
growth and increased resistance to apoptosis. Indeed, overex-
pression of ORAI3, on the one hand, disrupts normal homomul-
timerization of ORAI1, leading to the decreased density of SOCs
and, on the other hand, favors heteromultimerization of ORAI3
and ORAI1, resulting in the derivation of ARC-like AA-regulated
channels. Thus, controlling ORAI3 expression can be viewed
as a promising strategy in PCa treatment. This notion is sup-
ported by the results obtained from mouse prostate tumors.
ORAI3 was also recently implicated in the promotion of prolif-
eration and apoptosis resistance of HBC cells (Faouzi et al.,
2011; Motiani et al., 2013). This was attributed to the fact
that ORAI3 represents the main SOCE pathway in MCF-7 and30 Cancer Cell 26, 19–32, July 14, 2014 ª2014 Elsevier Inc.T47D HBC cell lines, but not in the normal MCF-10A cells. How-
ever, it remains unclear how the same Ca2+ entry channel can be
simultaneously engaged in two processes with different Ca2+
dependence. Our data indicate that in PCa cells ORAI3 deter-
mines the oncogenic switch between two Ca2+-channel pheno-
types: AA-regulated and store-operated ones, of which the
former is important for proliferation and the latter is important
for apoptosis providing a solution to controversies in the litera-
ture as to the involvement of the ORAI3 channel in SOCE and
the role of ORAI3 in cancer progression. We demonstrate that
at least two factors control the formation of ORAI monomers
or heteromers, namely the channel expression ratio and AA
metabolism. Depending on the structure of the channel formed,
ORAI channels can function as: (1) a SOC; (2) a constitutively
open channel; or (3) a channel activated by AA metabolism. In
contrast to Holzmann et al. (2013), we show the overexpression
of ORAI3 in cancer tissues leading to the appearance of Ca2+
signaling dependent on the endogenous levels and production
of AA. Therefore, we establish an oncogenic role for the ORAI3
channel and a mechanism via which AA metabolism is involved
in prostate oncogenesis.
EXPERIMENTAL PROCEDURES
Cell Culture
The human PCa cell lines LNCaP, DU-145, and PC-3 were obtained from
the American Type Culture Collection and maintained in culture in RPMI
1640 medium (Gibco-Life Technologies) supplemented with 10% fetal calf
serum (Seromed, Poly-Labo), 5 mM L-glutamine (Sigma), and kanamycin
100 mg/ml. LNCaP C4-2 cell line was a generous gift from Dr. F. Cabon. Cells
were grown at 37C in a humidified atmosphere containing 5% CO2. The
medium was replaced every 48 hr.
Cancer Tissue Sampling
Prostate tissue samples (prostate adenocarcinoma) were obtained from 15
patients with a mean age of 62.4 years (ranging from 51 to 70) who underwent
radical prostatectomy between January 2004 and June 2008 in the depart-
ment of Urology at Hospital Centre Lyon-Sud (The detailed procedure is
presented in Supplemental Experimental Procedures). Noninterventional
biomedical research protocol for tissue sample conservation after prostate
surgery has been set up at the Centre Hospitalier Lyon-Sud, and the Ethics
Committee in Lyon (CPP Sud-Est 2) specifically approved it for this study.
The patients admitted to the urology department in the Centre Hospitalier
Lyon-Sud were informed and gave voluntary, signed informed consent prior
to any tissue sample conservation and for research use.
Electrophysiology and Solutions
The composition of the extracellular solution for patch-clamp recording was
120 mM NaCl, 5 mM KCl, 10 mM CaCl2, 2 mM MgCl2, 5 mM glucose, and
10 mM HEPES, pH 7.4 (adjusted with tetraethylammonium hydroxide), osmo-
larity was 310 mOsm/kg adjusted with D-mannitol. The patch pipettes were
filled with the basic intracellular pipette solution: 120mMcesium-methane sul-
fonate, 10 mM CsCl, 10 mM HEPES, 10 mM 1.2-bis(2-aminophenoxy)ethane
N,N,N0,N0-tetraacetic acid (BAPTA), and 6 mM MgCl2 (pH adjusted to 7.4
with CsOH, and osmolarity was 295 mOsm/kg adjusted with D-mannitol). In
whole-cell, patch-clamp experiments for measuring membrane current in
response to AA, CaCl2 was added to the previous solution to achieve the
desired free Ca2+ concentration (100 nM) as computed with Maxchelator.
The experiments were carried out at room temperature.
Calcium Imaging
Cells were plated onto glass coverslips and were loaded with 4 mM Fura-2 AM
at room temperature for 45 min in the growth medium. Recordings were
performed in Maxchelator containing 140 mM NaCl, 5 mM KCl, 2 mM
Cancer Cell
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10 mM HEPES adjusted to pH 7.4 with NaOH. Fluorescence images of the
cells were recordedwith a video image analysis system (Quanticell). In Figure 1
and Figure S1, cells were preincubated for 10 min with TG (1 mM) in Ca2+-free
medium to deplete ERCa2+ store and then exposed to 2mMextracellular Ca2+
to induce SOCE seen as [Ca2+]c elevation. In Figure 3C, IM was applied to
Ca2+-free medium in the presence of two mitochondrial inhibitors, oligomycin
(40 mM) and rotenone (20 mM).
Immunocytochemistry
Sixty percent confluent PC3 cells were washed with 13 PBS. After, PC3 cells
were fixed with 4% formaldehyde-13 PBS for 15 min on ice. After three
washes with 13 PBS, cells were either incubated in PBS-gelatin (PBS with
1.2% gelatin) complemented with 0.01% Tween 20 and 100 mM glycine for
30 min at 37C. Afterward, the cells were incubated with a primary mouse
monoclonal anti-ORAI1 antibody at 4C overnight and a primary rabbit poly-
clonal anti-ORAI3 antibody at 37C for 30 min. After thorough washes in
PBS-gelatin, the slides were treated with the corresponding Alexa Fluor 546-
labeled anti-rabbit IgG and Alexa Fluor 488-labeled anti-mouse IgG (using
the dilution 1:4,000) diluted in PBS-gelatin for 1 hr at room temperature. After
two washes in PBS-gelatin and one in PBS, the slides were mounted with
Mowiol.
Western Blot
Protein samples (50 mg) were subjected to SDS-PAGE and transferred to a
nitrocellulose membrane by semi-dry western blotting (Bio-Rad). The mem-
brane was blocked in TNT buffer (Tris-HCl, pH 7.5, 140 mM NaCl, and
0.05% Tween 20) containing 5% milk for 45 min at room temperature.
Then membranes were gently incubated overnight at 4C with specific pri-
mary antibodies (see Supplemental Experimental Procedures). After three
5 min washes in TNT buffer, membranes were transferred into anti-rabbit
IgG horseradish peroxidase-linked secondary antibodies (Chemicon, 1/
50,000) or anti-mouse horseradish peroxidase-linked secondary antibodies
(Chemicon, 1/10,000) for 1 hr at room temperature. After three 15 min washes
in TNT buffer, the membrane was processed for chemiluminescent detection
using Supersignal West Dura chemiluminescent substrate (Pierce), according
to the manufacturer’s instructions. A detailed method of immunoprecipitation
and biotinylation of cell-surface membrane proteins is presented in Supple-
mental Experimental Procedures. Quantifications have been done using
ImageJ software. First, each relative density of band is normalized to its stan-
dard (b-actin or calnexin) to take into account loading variation. The values
present in western blot figures represent the relative density of bands
compared to the control condition, which will obviously have a relative den-
sity of 1.
Animals, siRNA Injection, and Tumorigenicity Assays
Studies involving animals, including housing and care, method of euthanasia,
and experimental protocols, were conducted in accordance with the local an-
imal ethical committee in the animal house (C59-00913; protocol CEEA
202012) of the University of Sciences and Technologies of Lille, under the
supervision of Dr. Lehen’kyi (59-009270). Tumor cells (2 3 106 cells/mouse)
were injected subcutaneously in 50% (v:v) Matrigel (BD Biosciences) to 6- to
8-week-old male nude mice, and tumors were measured every day. When
tumors grew exponentially, siRNA diluted in PBS was injected i.p. on a daily
basis (120 mg/kg). Tumor volume was estimated by the following formula:
length 3 width2 3 0.5.
Quantitative Real-Time PCR
Quantitative real-time PCR of mRNA transcripts was done using MESA
GREEN qPCR MasterMix Plus for SYBR Assay (Eurogentec) on the Bio-Rad
CFX96 real-time PCR detection system. The primers used for quantitative
PCR assays and siRNA sequences targeting hOrai or hSTIM1 are detailed in
Supplemental Experimental Procedures.
Cell Proliferation
Cell proliferation was measured using the CellTiter 96 Aqueous One Solution
cell proliferation assay (Promega). During proliferation assays, the cells were
cultured in low serum condition (1% fetal calf serum).Cell Cycle
Approximately 106 cells were fixed with 1 ml of ice-cold 70% methanol for
30 min. After fixing, cells were pelleted by centrifugation, washed three times
with PBS at 4C, resuspended in 100 ml of PBS, treated with 100 ml of RNase A
(1 mg/ml; Sigma), and stained with propidium iodide (Sigma) at a final concen-
tration of 50 mg/ml. The stained samples were measured on a FACScan flow
cytometer (Becton-Dickinson).
Apoptosis Assay
The level of apoptosis was estimated from the number of apoptotic nuclei
revealed by Hoechst staining.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2014.04.025.
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